VantroMarket Overview
← All markets
Health Market Overview

Oman

Last updated: November 2026
Regulatory Body
Directorate General of Pharmaceutical Affairs and Drug Control, Ministry of Health, Sultanate of Oman
Typical Timeline
6-18 months
Regulatory Overview

The primary regulatory authority for health products in Oman is the Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC), operating under the Ministry of Health (MoH). The legal framework is principally governed by the Pharmaceutical Law (Royal Decree No. 46/2012) and its associated regulations, which establish requirements for the registration, importation, distribution, and post-market surveillance of pharmaceuticals, medical devices, diagnostics, and increasingly, digital health solutions. All health products must obtain marketing authorization from the DGPADC prior to commercial sale or distribution in Oman. The registration process involves submission of a formal application dossier, technical evaluation by the DGPADC, and, where required, inspection of manufacturing facilities. Oman is an active member of the Gulf Cooperation Council (GCC) and participates in the GCC Centralized Drug Registration (CDR) program administered through the Gulf Health Council, which allows manufacturers to seek harmonized registration across member states including Oman, thereby reducing duplication of submission efforts.

Applications must be submitted through a locally licensed pharmaceutical agent or authorized representative registered with the MoH, as direct foreign manufacturer submissions are not accepted without a local entity. Technical dossiers are accepted in Common Technical Document (CTD) format, and the DGPADC increasingly references ICH guidelines as well as WHO standards for pharmaceutical products. For medical devices, Oman aligns broadly with GCC Medical Device Technical Regulation (MDTR) requirements, and devices are classified into risk-based categories with corresponding documentation requirements. Evidence of approval from a recognized stringent regulatory authority (SRA) such as the US FDA, EMA, or Health Canada can expedite review. Recent reforms have included digitization of submission portals, strengthened pharmacovigilance reporting obligations, and the introduction of conditional or provisional registration pathways for products addressing urgent public health needs, reflecting lessons drawn from the COVID-19 pandemic response.

Procurement Overview

Public procurement of health products in Oman is centrally coordinated through the Ministry of Health, which manages the national formulary, tender processes, and supply chain for government health facilities including hospitals, polyclinics, and primary care centers operated by the MoH. The Central Medical Stores (CMS) plays a critical operational role in warehousing and distributing procured products across the public health network. Tenders are governed by the Public Procurement Law (Royal Decree No. 36/2008 and subsequent amendments) and are administered through the MoH's procurement directorate, with larger or strategically significant contracts sometimes involving the National Tender Board or the Ministry of Finance. Oman also participates in joint GCC procurement initiatives coordinated through the Gulf Health Council, enabling collective negotiation and bulk purchasing of pharmaceuticals and vaccines to achieve economies of scale. Inclusion on the national essential medicines list or approved device formulary is a prerequisite for consideration in public tender processes, making prior registration with the DGPADC an essential first step for any supplier targeting the public sector.

The private healthcare sector in Oman is a growing procurement channel, encompassing private hospitals, polyclinics, pharmacies, and diagnostic centers concentrated primarily in Muscat and other urban centers. Private sector buyers procure independently through licensed importers and distributors, with purchasing decisions influenced by clinician preference, price competitiveness, and product registration status. Oman does not have a significant presence of major multilateral donor-funded procurement programs such as those administered by UNICEF Supply Division, the Global Fund, USAID, or Gavi, given its upper-middle-income country classification and relatively well-resourced public health system. However, Oman has engaged with international organizations for technical assistance and capacity building in specific areas such as vaccine management and health system strengthening. Local manufacturing capacity remains limited, and Oman does not currently apply formal local manufacturing preference policies in its tender evaluations, though national health strategies have articulated ambitions to develop domestic pharmaceutical production capacity as part of broader economic diversification efforts aligned with Vision 2040.

Go deeper

This is a generic market overview. For a structured entry brief tailored to your product category, including regulatory pathway, pricing, and risk assessment, use the Market Brief tool.

Generate a free Market Brief for Oman →
Market overview generated by AI and updated monthly. Verify with in-country regulatory authorities before making market entry decisions.